The anti-inflammatory phospholipid, ONO2 - an approach to cure for diabetes


Dr. Abdesalam Azem (PI) - TRDC


Type 2 diabetes (T2D) is a metabolic disorder, which is caused by insulin resistance, mainly of the adipose, liver and muscle tissues. Tumor necrosis factor a (TNFa) is a key pro-inflammatory cytokine which directly contributes to the initiation and development of insulin resistance and T2D. Accordingly, anti-TNFa therapy was partially successful in reversing insulin resistance in animal models of T2D. The limited efficacy of TNFa neutralizing drugs in animal models and in human clinical trials, prompt us to investigate the feasibility of an improved anti-TNFa therapy for T2D. We propose here to study the mechanism of activity of a promising anti-inflammatory small molecular weight drug, named ONO2, which blocks the production of TNFa, and also modulates the production of other key pro- and anti-inflammatory cytokines. We further propose to test the efficacy of ONO2, in the treatment of T2D animal model. We anticipate thatelucidation of the signal transduction pathway of ONO2 will lead to the development of new drugs that may help cure diabetes.